Northwest Biotherapeutics Q2 Earnings Snapshot - Darien Times
| NWBO Stock | USD 0.28 0.01 3.70% |
About 55% of Northwest Biotherapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Northwest Biotherapeutics otc stock suggests that some investors are interested at this time. Northwest Biotherapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Northwest Biotherapeutics. Many technical investors use Northwest Biotherapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Northwest |
Northwest Biotherapeutics Q2 Earnings Snapshot Darien Times
Read at news.google.com
 |
Northwest Biotherapeutics Fundamental Analysis
We analyze Northwest Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Northwest Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Northwest Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Northwest Biotherapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Northwest Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Northwest Biotherapeutics otc stock to make a market-neutral strategy. Peer analysis of Northwest Biotherapeutics could also be used in its relative valuation, which is a method of valuing Northwest Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Northwest Biotherapeutics Related Equities
| PYPD | PolyPid | 3.45 | ||||
| LTRN | Lantern Pharma | 2.50 | ||||
| CUE | Cue Biopharma | 2.34 | ||||
| ANNX | Annexon | 2.19 | ||||
| RVPH | Reviva Pharmaceuticals | 0.56 | ||||
| ZURA | Zura Bio | 1.67 | ||||
| WVE | Wave Life | 2.83 | ||||
| GANX | Gain Therapeutics | 3.80 | ||||
| INMB | INmune Bio | 4.02 | ||||
| ANIX | Anixa Biosciences | 6.59 |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.